825 related articles for article (PubMed ID: 26062519)
1. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration of VEGF and PDGF-AA in patients with active thyroid orbitopathy before and after immunosuppressive therapy.
Nowak M; Marek B; Karpe J; Kos-Kudla B; Sieminska L; Kajdaniuk D; Treszer M
Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):582-6. PubMed ID: 25140996
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy.
Mysliwiec J; Palyga I; Nikolajuk A; Kowalska A; Gorska M
Endokrynol Pol; 2012; 63(2):92-6. PubMed ID: 22538746
[TBL] [Abstract][Full Text] [Related]
4. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VEGF) in the blood of healthy people and patients with Graves' orbitopathy--a new mechanism of glucocorticoids action?
Kajdaniuk D; Marek B; Niedziołka-Zielonka D; Foltyn W; Nowak M; Siemińska L; Borgiel-Marek H; Głogowska-Szeląg J; Ostrowska Z; Drożdż L; Kos-Kudła B
Endokrynol Pol; 2014; 65(5):348-56. PubMed ID: 25301484
[TBL] [Abstract][Full Text] [Related]
6. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
7. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
9. Serum pro- and anti-inflammatory cytokines in patients with Graves' disease with ophthalmopathy during treatment with glucocorticoids.
Myśliwiec J; Kretowski A; Szelachowska M; Mikita A; Kinalska I
Rocz Akad Med Bialymst; 1999; 44():160-9. PubMed ID: 10697431
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves' orbitopathy: A preliminary study.
Kościuszko M; Popławska-Kita A; Pawłowski P; Lipińska D; Hryniewicka J; Jankowska D; Górska M; Krętowski A; Myśliwiec J
Adv Med Sci; 2021 Sep; 66(2):315-320. PubMed ID: 34256242
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy.
Londzin-Olesik M; Kos-Kudla B; Karpe J; Nowak A; Nowak M
Exp Clin Endocrinol Diabetes; 2021 Oct; 129(10):762-769. PubMed ID: 33157557
[TBL] [Abstract][Full Text] [Related]
12. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I
Int Immunopharmacol; 2003 Apr; 3(4):549-52. PubMed ID: 12689659
[TBL] [Abstract][Full Text] [Related]
14. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
16. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy.
Myśliwiec J; Adamczyk M; Pawłowski P; Nikołajuk A; Górska M
Endokrynol Pol; 2007; 58(2):105-9. PubMed ID: 17578825
[TBL] [Abstract][Full Text] [Related]
17. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy].
Myśliwiec J; Kretowski A; Topolska J; Stepień A; Kinalska I
Pol Arch Med Wewn; 2002 Aug; 108(2):739-44. PubMed ID: 12476893
[TBL] [Abstract][Full Text] [Related]
18. [The influence of hyperthyroidism and glucocorticosteroid treatment on bone metabolism in patients with Graves' disease and ophthalmopathy].
Kaźmierczyk-Puchalska A; Kulig G; Krzyzanowska-Swiniarska B; Pilarska K
Endokrynol Pol; 2005; 56(3):259-64. PubMed ID: 16350719
[TBL] [Abstract][Full Text] [Related]
19. The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy.
Lacka K; Manuszewska E; Korczowska I; Lacki JK
Curr Eye Res; 2007 Mar; 32(3):291-7. PubMed ID: 17453949
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
